Home > Boards > US Listed > Medical - Healthcare > China Cord Blood Corp (CO)

China Cord Blood and Golden Meditech Holdings Limited

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 9/23/2019 8:50:38 AM
Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 5, 2019 PR Newswire (US) - 9/20/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/27/2019 4:25:21 PM
Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2020 PR Newswire (US) - 8/27/2019 4:16:00 PM
The Committee for China Cord Fairness Launches Consent Solicitation at Global Cord Blood Corporation PR Newswire (US) - 8/27/2019 9:00:00 AM
Global Cord Blood Corporation to Report First Quarter Fiscal 2020 Financial Results PR Newswire (US) - 8/21/2019 7:00:00 AM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 8/14/2019 6:35:20 AM
Global Cord Blood Corporation (NYSE: CO) Urged To Explain Management Compensation in Third Letter From Shareholder Group PR Newswire (US) - 8/7/2019 9:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 7/23/2019 4:19:02 PM
Global Cord Blood Corporation Files Its Annual Report on Form 20-F PR Newswire (US) - 7/23/2019 4:16:00 PM
Global Cord Blood Corporation (NYSE: CO) Urged in Second Letter From Shareholder Group to Protect Minority Shareholders PR Newswire (US) - 7/17/2019 9:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/18/2019 4:34:04 PM
Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2019 PR Newswire (US) - 6/18/2019 4:16:00 PM
Shareholder of Global Cord Blood Corporation (NYSE: CO) Hires Global Law Firm, The Seiden Group, to Help Investigate and Enfo... PR Newswire (US) - 6/17/2019 10:56:00 PM
Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2019 Financial Results PR Newswire (US) - 6/11/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/6/2019 6:12:14 AM
Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal PR Newswire (US) - 6/6/2019 6:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 8:28:45 AM
Global Cord Blood Corporation Announces Receipt of Preliminary Non-Binding Proposal to Acquire the Company PR Newswire (US) - 6/4/2019 8:16:00 AM
Global Cord Blood Corporation Raised Subscription Fee PR Newswire (US) - 4/1/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/25/2019 4:26:57 PM
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2019 PR Newswire (US) - 2/25/2019 4:16:00 PM
Global Cord Blood Corporation to Report Third Quarter and First Nine Months Fiscal 2019 Financial Results PR Newswire (US) - 2/19/2019 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 6:05:33 AM
Amended Report of Foreign Issuer (6-k/a) Edgar (US Regulatory) - 12/7/2018 7:06:14 AM
mlkrborn   Tuesday, 09/18/12 01:30:53 PM
Re: None
Post # of 429 
China Cord Blood and Golden Meditech Holdings Limited enter into convertible note financing to further expand cord blood banking services; Mr. Yuen Kam will be appointed as Chairman (CO) 2.67 : Co and Golden Meditech Holdings, an integrated healthcare enterprise in China, announced that they entered into agreements under which Golden Meditech is expected to invest $50 million into CCBC to support its further business expansion and to capitalize on China's fast-growing healthcare services industry. The convertible note carries a 7% interest per annum and a total rate of return of 12% per annum. The convertible note holder can convert the convertible note into ordinary shares of the Company at a conversion price of $2.838. The total ordinary shares issuable represents approximately 15.5% of the enlarged share capital of the Company. Upon completion of the transaction, Mr. Yuen Kam, will be appointed as Chairman of CCBC and Ms. Ting Zheng will continue her role as the Chief Executive Officer of CCBC. Mr. Yuen Kam is currently the Chairman and Chief Executive Officer of Golden Meditech.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist